Risk assessment in pulmonary arterial hypertension
- PMID: 29599117
- DOI: 10.1183/13993003.02606-2017
Risk assessment in pulmonary arterial hypertension
Conflict of interest statement
Conflict of interest: M.M. Hoeper reports receiving personal fees from Actelion, Bayer, GSK, Pfizer, Gilead and Merck, during the conduct of the study. Conflict of interest: D. Pittrow reports receiving personal fees from Actelion, Aspen, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Pfizer and AstraZeneca, outside the submitted work. Conflict of interest: C. Opitz reports receving personal fees from Actelion, Bayer, GSK, Pfizer and Novartis, during the conduct of the study. Conflict of interest: J.S.R. Gibbs reports receiving personal fees from Actelion, Bayer, GSK, Pfizer, MSD, Bellerophon and Arena, during the conduct of the study. Conflict of interest: S. Rosenkranz reports receving grants and personal fees from Actelion, Bayer, Pfizer, Novartis and United Therapeutics, and personal fees from GSK, Gilead and MSD, during the conduct of the study. Conflict of interest: E. Grünig reports receiving personal fees from Actelion, Bayer, GSK, Pfizer, United Therapeutics and MSD, outside the submitted work. Conflict of interest: K.M. Olsson reports receiving personal fees from Actelion, Bayer, GSK, Pfizer and United Therapeutics, during the conduct of the study. Conflict of interest: D. Huscher reports receiving personal fees from Actelion outside the submitted work.
Comment in
-
Risk assessment in pulmonary arterial hypertension.Eur Respir J. 2018 Mar 29;51(3):1800279. doi: 10.1183/13993003.00279-2018. Print 2018 Mar. Eur Respir J. 2018. PMID: 29599118 No abstract available.
Comment on
-
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.Eur Respir J. 2017 Aug 3;50(2):1700740. doi: 10.1183/13993003.00740-2017. Print 2017 Aug. Eur Respir J. 2017. PMID: 28775047
-
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.Eur Respir J. 2017 Aug 3;50(2):1700889. doi: 10.1183/13993003.00889-2017. Print 2017 Aug. Eur Respir J. 2017. PMID: 28775050
Similar articles
-
Validation of a risk assessment instrument for pulmonary arterial hypertension.Eur Heart J. 2018 Dec 14;39(47):4182-4185. doi: 10.1093/eurheartj/ehx301. Eur Heart J. 2018. PMID: 28637288 No abstract available.
-
Risk assessment in pulmonary arterial hypertension.Eur Respir J. 2018 Mar 29;51(3):1800279. doi: 10.1183/13993003.00279-2018. Print 2018 Mar. Eur Respir J. 2018. PMID: 29599118 No abstract available.
-
[Echocardiography and other imaging modalities in pulmonary arterial hypertension].Anadolu Kardiyol Derg. 2010 Aug;10 Suppl 1:27-35. doi: 10.5152/akd.2010.116. Anadolu Kardiyol Derg. 2010. PMID: 20819764 Review. Turkish.
-
Prognostic Stratification and Treatment for Pulmonary Arterial Hypertension. Gaps and Promising Remedies.Arch Bronconeumol. 2023 Oct;59(10):617-618. doi: 10.1016/j.arbres.2023.04.003. Epub 2023 Apr 20. Arch Bronconeumol. 2023. PMID: 37147267 English, Spanish. No abstract available.
-
Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis.J Am Soc Echocardiogr. 2013 Jan;26(1):1-14. doi: 10.1016/j.echo.2012.10.009. Epub 2012 Nov 8. J Am Soc Echocardiogr. 2013. PMID: 23140849 Review.
Cited by
-
Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study.J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1501-1512. doi: 10.1002/jcsm.12764. Epub 2021 Sep 9. J Cachexia Sarcopenia Muscle. 2021. PMID: 34498427 Free PMC article.
-
Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?J Clin Med. 2021 Jun 26;10(13):2826. doi: 10.3390/jcm10132826. J Clin Med. 2021. PMID: 34206876 Free PMC article. Review.
-
The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.Eur Respir Rev. 2024 Mar 20;33(171):230183. doi: 10.1183/16000617.0183-2023. Print 2024 Jan 31. Eur Respir Rev. 2024. PMID: 38508664 Free PMC article. Review.
-
Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review.J Am Heart Assoc. 2024 Jul 2;13(13):e034151. doi: 10.1161/JAHA.123.034151. Epub 2024 Jun 21. J Am Heart Assoc. 2024. PMID: 38904230 Free PMC article.
-
Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing.J Clin Med. 2023 Oct 29;12(21):6840. doi: 10.3390/jcm12216840. J Clin Med. 2023. PMID: 37959305 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical